% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tinhofer:274468,
      author       = {I. Tinhofer$^*$ and S. Staudte$^*$ and S. George$^*$},
      title        = {{L}iquid biopsy in head neck cancer: ready for clinical
                      routine diagnostics?},
      journal      = {Current opinion in oncology},
      volume       = {35},
      number       = {3},
      issn         = {1040-8746},
      address      = {[Erscheinungsort nicht ermittelbar]},
      publisher    = {Ovid},
      reportid     = {DKFZ-2023-00613},
      pages        = {151-157},
      year         = {2023},
      note         = {2023 May 1;35(3):151-157},
      abstract     = {The bodily fluids of patients with solid cancers
                      representing a minimally-invasive source of clinically
                      exploitable biomarkers have attracted an increasing amount
                      of attention in recent years. In patients with head and neck
                      squamous cell carcinoma (HNSCC), cell-free tumour DNA
                      (ctDNA) belongs to the most promising liquid biomarkers for
                      monitoring disease burden and identifying patients at high
                      risk of recurrence. In this review, we highlight recent
                      studies, evaluating the analytical validity and clinical
                      utility of ctDNA as a dynamic biomarker in HNSCC, especially
                      as it relates to risk stratification and contrasting human
                      papilloma virus (HPV+ and HPV-) and carcinomas.The clinical
                      potential of minimal residual disease monitoring through
                      viral ctDNA in identifying HPV+ oropharyngeal carcinoma
                      patients at higher risk of recurrence has recently been
                      demonstrated. Furthermore, accumulating evidence supports a
                      potential diagnostic value of ctDNA dynamics in HPV-negative
                      HNSCC. Altogether, recent data suggest that ctDNA analysis
                      may be a valuable tool in guiding (de)escalation of surgical
                      interventions as well as adaptation in radiotherapy dosage,
                      both in the definitive and adjuvant settings.Rigorous
                      clinical trials with patient-relevant endpoints are critical
                      in order to demonstrate that treatment decisions based on
                      ctDNA dynamics result in better outcomes in HNSCC.},
      subtyp        = {Review Article},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36966499},
      doi          = {10.1097/CCO.0000000000000935},
      url          = {https://inrepo02.dkfz.de/record/274468},
}